Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Timdarpacept - ImmuneOnco Biopharma

Next Previous
Drug Profile

Timdarpacept - ImmuneOnco Biopharma

Alternative Names: IMC-001 - ImmuneOnco Biopharma; IMM-01 - ImmuneOnco Biopharma; IMM01; SIRPαFc - ImmuneOnco Biopharma

Latest Information Update: 17 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ImmuneOnco Biopharma
  • Developer ImmuneOnco Biopharma; Institute of Hematology & Blood Diseases Hospital
  • Class Antineoplastics; Immunoglobulin fusion proteins; Immunotherapies; Recombinant fusion proteins; Vascular disorder therapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD47 antigen inhibitors; Macrophage stimulants; Phagocyte stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic myelomonocytic leukaemia; Hodgkin's disease
  • Phase II Atherosclerosis
  • Phase I/II Acute myeloid leukaemia; Myelodysplastic syndromes; Solid tumours

Most Recent Events

  • 12 Sep 2025 ImmuneOnco Biopharma plans a phase-I/II trial for Solid tumours (Combination therapy, Late-stage disease, Second-line therapy or greater) in China (IV), in October 2025 (NCT07170787)
  • 30 May 2025 Efficacy data from a phase I/II trial in Myelodysplastic syndrome presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)
  • 30 May 2025 Adverse events and efficacy data from a phase I/II trial in Lymphoma presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top